HighTide Therapeutics, today announced that it has been invited to deliver two presentation at Phar-East 2019, to be held March 18–20 in Singapore.
May 11, 2019
Learn More
Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
April 24, 2019
Learn More
Jeffrey Dao, Operations & Business Development Officer to present HighTide’s HTD1801 for primary sclerosing cholangitis (PSC) at the World Orphan Drug Congress USA 2019 in Oxon Hill, MD...
April 04, 2019
Learn More
[Rockville, Maryland, Dec. 11, 2018] — HighTide Therapeutics, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9.
December 11, 2018
Learn More
[Rockville, Maryland, Nov. 27, 2018] — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced that the U.S. FDA has granted Fast Track Designation to its investigational new drug, HTD1801...
November 27, 2018
Learn More
[Rockville, Maryland, October 3, 2018] — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company participated in the 2nd Annual Pediatric Autoimmune Liver Disease Symposium and...
October 03, 2018
Learn More
We will contact you as soon as possible
© 2024 HighTide Therapeutics, Inc.